333 related articles for article (PubMed ID: 27479184)
1. Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.
Dragoș ML; Ivanov IC; Mențel M; Văcărean-Trandafir IC; Sireteanu A; Titianu AA; Dăscălescu AS; Stache AB; Jitaru D; Gorgan DL
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886877
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.
Paíno T; Paiva B; Sayagués JM; Mota I; Carvalheiro T; Corchete LA; Aires-Mejía I; Pérez JJ; Sanchez ML; Barcena P; Ocio EM; San-Segundo L; Sarasquete ME; García-Sanz R; Vidriales MB; Oriol A; Hernández MT; Echeveste MA; Paiva A; Blade J; Lahuerta JJ; Orfao A; Mateos MV; Gutiérrez NC; San-Miguel JF
Leukemia; 2015 May; 29(5):1186-94. PubMed ID: 25388955
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
7. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
11. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
[TBL] [Abstract][Full Text] [Related]
12. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
13. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B; Vidriales MB; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; González Y; Bladé J; Lahuerta JJ; Orfao A; San-Miguel JF;
Blood; 2009 Nov; 114(20):4369-72. PubMed ID: 19755674
[TBL] [Abstract][Full Text] [Related]
14. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
Paiva B; Paino T; Sayagues JM; Garayoa M; San-Segundo L; Martín M; Mota I; Sanchez ML; Bárcena P; Aires-Mejia I; Corchete L; Jimenez C; Garcia-Sanz R; Gutierrez NC; Ocio EM; Mateos MV; Vidriales MB; Orfao A; San Miguel JF
Blood; 2013 Nov; 122(22):3591-8. PubMed ID: 24072855
[TBL] [Abstract][Full Text] [Related]
15. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Paiva B; Corchete LA; Vidriales MB; Puig N; Maiso P; Rodriguez I; Alignani D; Burgos L; Sanchez ML; Barcena P; Echeveste MA; Hernandez MT; García-Sanz R; Ocio EM; Oriol A; Gironella M; Palomera L; De Arriba F; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Lahuerta JJ; Blade J; Orfao A; Mateos MV; San Miguel JF;
Blood; 2016 Apr; 127(15):1896-906. PubMed ID: 26755711
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma-initiating cells.
Hosen N
Int J Hematol; 2013 Mar; 97(3):306-12. PubMed ID: 23420183
[TBL] [Abstract][Full Text] [Related]
18. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.
Rawstron AC; Davies FE; Owen RG; English A; Pratt G; Child JA; Jack AS; Morgan GJ
Br J Haematol; 1998 Jan; 100(1):176-83. PubMed ID: 9450807
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.
Demyanets S; Kaider A; Simonitsch-Klupp I; Bayer G; Subasic A; Thalhammer R; Esterbauer H; Krauth MT; Agis H; Reiter T; Schwarzinger I
Ann Hematol; 2020 Nov; 99(11):2599-2609. PubMed ID: 32935190
[TBL] [Abstract][Full Text] [Related]
20. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]